After the change in the Cabinet, the President travels to Mexico

President Alberto Fernández will travel to Mexico tomorrow night to participate next Wednesday in the events commemorating the 200 years of that country’s independence, an occasion for which he was specially invited by his partner Andrés López Obrador, and to hold various meetings bilateral.

The head of state will be one of the speakers in the official activity, « in attention to the strong ties of collaboration and friendship between both countries and by virtue of the common historical aspects between our nations in the fight for independence, » according to the invitation letter sent by the government of Mexico.

The President will be accompanied by Foreign Minister Felipe Solá; the Minister of Economy, Martín Guzmán; the Deputy Chief of Cabinet, Cecilia Todesca; the Secretary for Strategic Affairs of the Presidency, Gustavo Beliz; the Secretary General of the Presidency, Julio Vitobello, and the Secretary of Communication and Press, Juan Pablo Biondi.

« The issue of the Latin American process, the region and the new role of Mexico will be very present throughout this visit, » said the Argentine ambassador to Mexico, Carlos Tomada, in dialogue with . Radio, and advanced: « This trip has a imprint of launch for the deepening of relations « .

The presidential agenda includes a visit to the Mexican Senate and a meeting with the head of government of the Federal District, Claudia Sheinbaum, is also scheduled.


AstraZeneca Vaccine: Lab Visit


In addition, Fernández will visit the Liomont laboratory with López Obrador, reported official sources. On August 12, the President had announced an agreement with Mexico for the shipment by Argentina of the active substance necessary for the development of thea coronavirus vaccine created by the Swedish-British pharmaceutical company AstraZeneca and the University of Oxford.

This substance is produced by the Argentine laboratory mAbxience, belonging to the Grupo Insud of the businessman Hugo Sigman, for subsequent packaging in the Liomont laboratory in Mexico.

In the night of that August 12, Fernández contacted López Obrador by telephone and on that occasion both shared « the enthusiasm to jointly face the development and manufacture of the vaccine », in order to prevent the coronavirus in Latin America.

The first shipment of the active substance from the AstraZeneca vaccine arrived in Mexico City on January 20, through an air shipment with 5,230 liters; while on February 2, the second shipment from Argentina arrived in the Federal District, for the packaging of six million doses and their distribution in the region.


How many doses of the vaccine will be produced

Liomont plans to reach a maximum production point of around 685,000 daily doses, according to the official announcement by Mexican authorities.

The strategy of joint production of the vaccine developed by AstraZeneca and the University of Oxford received a strong boost from the agreement of both governments, plus the participation of the Carlos Slim Foundation, Mexican telecommunications magnate

The goal is to produce between 150 and 200 million doses of the vaccine to be distributed throughout Latin America and the Caribbean; With the exception of Brazil, which has agreements with other international suppliers.

The agreement between the two countries to develop the AstraZeneca vaccine was, in effect, one of the topics of conversation in the interview that the President held on February 7 with two envoys from the López Obrador government.

They were the undersecretary of Prevention and Health Promotion of Mexico, Hugo López-Gatell, and the director general of Regional American Organizations and Mechanisms of the Ministry of Foreign Relations (equivalent to the Foreign Ministry), Efraín Guadarrama Pérez.

With both officials, Fernández analyzed the vaccination plans and the agreement for the development of the vaccine. Also iThey exchanged information about the Russian Sputnik V vaccine, Since in recent weeks Mexico was interested in acquiring massive batches of the drug created by the Gamaleya Institute.